A Phase 1 open-label study to investigate the pharmacodynamics, metabolomics and pharmacokinetics of CUDC-101 in subjects with HER2 positive invasive breast cancer.
Phase of Trial: Phase I
Latest Information Update: 15 Jan 2013
At a glance
- Drugs CUDC 101 (Primary)
- Indications Breast cancer
- Focus Biomarker; Pharmacodynamics
- 15 Jan 2013 New trial record